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CHAPTER 1 
INTRODUCTION 
 
Value-Based Healthcare 
For decades, policy makers have been developing legislation in attempt to bend the 
healthcare cost curve to improve value while maintaining quality healthcare delivery.  The 
National Health Expenditure has grown steadily since the 1960s reaching 17.9% of the Gross 
Domestic Product (GDP) in 20161.    The Health Maintenance Act of 19732 promoted the 
formation of Health Maintenance Organizations (HMOs) and other managed care organizations 
which aimed to reduce healthcare costs through various techniques including capitation 
agreements for physicians, providing a set of services for fixed payment, restricting access 
outside of a preferred network and cost-sharing features such as copayments and coinsurance.  
The number of managed care organizations continued to grow in the 1980s and 1990s3.   
However, the quality of healthcare delivery in the United States began receiving intense 
scrutiny following the release of To err is human: Building a safe health system by the Institute 
of Medicine (IOM) in 19994.  In this report, the authors outline a healthcare system marred by 
preventable medical errors and patient safety concerns.  In their follow-up series, Crossing the 
Quality Chasm, the IOM raised awareness of the inherent disincentive of current healthcare 
payment policies to improve the value of healthcare delivery by reducing cost5.  In light of these 
two publications, policies supporting value based payment systems or “pay for performance” 
initiatives began to gain traction as a mechanism to support high quality care while also reducing 
cost6,7.   
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  The passage of the Affordable Care Act (ACA) in 2010 resulted in healthcare reform 
with the goal of reducing healthcare costs while enhancing the quality of care8.  Underlying this 
directive is a major transformation in the way healthcare is administered.  There is an ongoing 
transition from the traditional fee-for-service model of healthcare delivery in the United States to 
that of bundled payments and Accountable Care Organizations (ACOs).   With this, the 
reimbursement structure is changing such that the burden of providing high-quality, cost-
effective care falls on healthcare systems.  ACOs which meet established quality metrics become 
eligible for “incentive payments.8” Additionally, penalties in the form of reduction in payment 
will be imposed on systems which fail to meet accepted quality standards.  One such example, 
the Hospital Readmissions Reduction Program (HRRP), permits Centers for Medicare and 
Medicaid Services (CMS) to reduce reimbursement to hospitals with excess 30-day hospital 
unplanned readmissions8.   
The HRRP, established as a provision of the ACA, reflects the 2008 recommendations of 
the Medicare Payment Advisory Commission (MedPAC) in their report to Congress9.  In this 
report, MedPAC recognized that the current Medicare fee-for-service (FFS) payment model 
rewarded health care systems for increased volume.  They recommended a novel payment 
structure which would hold providers accountable for the delivery of high-quality care and 
incentivize providers to work together.  The proposed changes included public reporting of 
hospital readmission rates and a readmission reduction program, whereby Medicare would 
reduce payments to hospitals with excess readmissions.  With a 30-day readmission rate of 
approximately 20% (17.6%9, 19.6%10) among Medicare beneficiaries9,10, these changes were 
proposed to save Medicare as much as $12 billion on preventable readmissions while improving 
quality of care delivered9.   
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Since implementation of HRRP, penalties imposed on hospitals with excess readmissions 
increased from $290 million in 2013 to $528 million in 201711.  As additional medical conditions 
are added to the evaluation of the readmission penalty, the average hospital penalty and percent 
of hospitals receiving the maximum penalty continues to rise (table 1).  While these regulations 
resulted in significant savings for Medicare, the loss of revenue for hospitals has prompted them 
to focus attention on ways to reduce hospital readmissions and improve safety during transitions 
of care.   
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Table 1. Financial Summary from First Five Years of Hospital Readmission Reduction Program 
(Reproduced with permission11) 
 
Year penalties 
apply 
FY 2013 FY 2014 FY 2015 FY 2016 FY 2017 
Performance 
(measurement) 
period 
June 2008-
July 2011 
June 2009-
July 2012 
June 2010-
July 2013 
June 2011-
July 2014 
June 2012-
July 2015 
Diagnoses of 
initial 
hospitalization 
Heart attack 
Heart failure 
Pneumonia 
Heart attack 
Heart failure 
Pneumonia 
Heart attack 
Heart failure 
Pneumonia 
COPD 
Hip or knee 
replacement 
Heart attack 
Heart failure 
Pneumonia 
COPD 
Hip or knee 
replacement 
Heart attack 
Heart failure 
Pneumonia* 
(expanded) 
COPD 
Hip or knee 
replacement 
CABG 
Penalties: Percentage reduction in base payments on all Medicare inpatient admissions 
Maximum rate 
of penalty 
1% 2% 3% 3% 3% 
Average 
hospital 
payment 
adjustment 
(among all 
hospitals) 
-0.27% -0.25% -0.49% -0.48% -0.58% 
Average 
hospital 
penalty 
(among 
penalized 
hospitals only) 
-0.42% -0.38% -0.63% -0.61% -0.74% 
Percent of 
hospitals 
penalized 
64% 66% 78% 78% 79% 
Percent of 
hospitals at 
max penalty 
8% 0.6% 1.2% 1.1% 1.8% 
CMS estimate 
of total 
penalties 
$290 million $227 million $428 million $420 million $528 million 
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Diabetes in Hospitalized Patients 
The number of diabetes-related emergency department visits and hospitalizations has 
increased with the increasing prevalence of diabetes in the U.S12.  While only 9.4% of the U.S. 
population had diabetes in 201512,  25-30% of hospitalized patients have diabetes.13  Patients 
with diabetes incur higher hospital costs and longer lengths of stay compared with their non-
diabetic counterparts14.  They are also more likely to require hospitalization through the 
emergency department, another high-cost resource14. 
Several studies15–28 identify diabetes as an independent risk factor for hospital 
readmission.  These studies include a broad range of patient populations including those admitted 
for renal transplant15, vascular surgery29, coronary artery bypass graft (CABG) or other cardiac 
surgery16,17,21, congestive heart failure(CHF)22,23, acute myocardial infarction (AMI)24, any 
cardiovascular disease admission (AMI, CHF, ischemic heart disease, stroke)25, stroke26,27, liver 
disease28 and general medical patients19,20,30.  Compared to the general population whose 30-day 
readmission rate is 5-14%31–33, patients with diabetes have a 30-day readmission rate of 14.4-
22.7%31.  Anti-diabetic agents are some of the highest risk medications for causing emergency 
hospitalization for adverse drug events placing this patient population at even greater risk after a 
hospital discharge34. 
Inpatient diabetes education35, case management transition resources36 and inpatient 
medication adjustment to improve glycemic control37–39 may be effective interventions to reduce 
hospital readmission among patients with diabetes.  Understanding causes and trends of 
readmission in patients with type 2 diabetes (T2DM) has the potential to improve transition-of-
care strategies for this at-risk population.  Enhancing the quality of care delivery to patients with 
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diabetes during transitions of care has may reduce healthcare costs by avoiding preventable 
hospital readmissions.  
 
Predictive Analytics in Hospital Readmissions 
 As a result of regulations established through the HRRP, the literature abounds with 
strategies for reducing excess 30-day hospital readmission40,41.  In a review of the existing 
literature, Hanson et al established a terminology for classification of the types of interventions 
implemented based on the timing and setting of the interventions.  Under their model, 
interventions are classified as predischarge interventions, postdischarge interventions or bridging 
interventions.  Yet, given the heterogeneity of the patient populations, interventions and 
outcomes reviewed, they were unable to determine which individual components of an 
intervention were responsible for the desired effect41.  In the most comprehensive systematic 
review and meta-analysis of interventions to reduce 30-day readmissions to date, Leppin et al use 
the same classification framework and demonstrated that effective interventions are more 
complex, more comprehensive and increase a patient’s capacity for self-care40.  Higher 
complexity required more resources to implement the intervention and required a higher number 
of patient interactions.  Allocating these resource-intensive interventions to the highest-risk 
patients increases the effectiveness of readmission reduction programs42.   
Given the inability of health care providers to accurately anticipate patients with highest 
risk for readmission43, predictive analytics have been employed to aid in identification of highest 
risk patients.  Two systematic reviews44,45 describe 99 unique, published hospital readmission 
prediction models.  Using prediction models to target resources to high-risk patients has shown 
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benefit in heart failure patients where this approach significantly reduced readmissions from 
26.2% to 21.2%42.         
Before application in clinical practice, the quality of these predictions models must be 
assessed.  An evaluation of prediction models includes an assessment of various aspects of 
model performance, most commonly discrimination and calibration46.  Discrimination, how well 
the model separates those with the outcome from those without, is typically assessed using the 
concordance-statistic (c-statistic).  For a binary outcome, such as hospital readmission, this 
correlates to the area under the receiver operating characteristic (ROC) curve.  C-statistic values 
may range from 0.5 to 1.0, where 0.5 implies that the model’s ability to accurately discriminate 
is equivalent to chance and 1.0 implies perfect discrimination.  One proposed framework 
classifies a C-statistic of  >0.5 to <0.7 as poor discrimination,  ≥0.7 to <0.8 as acceptable 
discrimination,  ≥0.8 to <0.9 as excellent discrimination and ≥0.9 as outstanding 
discrimination47.  For calibration, the measure of agreement between observed and predicted 
outcomes, the evaluation method is more variable and not consistently reported in the biomedical 
literature44,45.   
Most of the studies describing readmission risk prediction models demonstrate only 
acceptable or poor discriminatory power.  In the systematic review of hospital readmission risk 
prediction models by Kansagara et al, 26 unique models were identified with c-statistic values 
ranging from 0.55 to 0.83.  However, only 6 models demonstrated a c-statistic greater than 
0.7044.  In a more recent systematic review by Zhou et al, 60 studies of 73 unique models 
reported a c-statistic range from 0.21 to 0.88.  Two studies reported a c-statistic of >0.8 
(excellent), 11 reported a c-statistic of ≥0.7 to <0.8 (acceptable) and all other studies 
demonstrated poor discrimination performance with a c-statistic <0.745.      
15 
 
In addition to their discriminatory performance, predictive models can be characterized 
by other features such as the development cohort, readmission outcome, variables included in the 
predictive model and the statistical algorithm(s) used to develop the model.   
Most commonly, the cohort is selected based on the diagnosis at index hospitalization, 
typically one or more of those penalized under the HRRP (i.e., CHF, pneumonia, COPD).  
Diagnosis-specific models are increasing in prevalence45 and demonstrate improved accuracy 
compared to models developed in more heterogeneous cohorts48.  Institution-specific risk 
readmission models are also common.  They may offer improved discrimination49 when 
compared with publically available models and those endorsed by CMS23,50 but suffer in the 
ability to generalize to other populations.       
Historically, there has been an overreliance on administrative billing data as features in 
readmission predictions models.  One significant limitation to that approach is the lack of the 
availability of that information at the time of hospital discharge limiting their use in real-time 
clinical decision-making.  The widespread implementation of electronic health records has 
increased electronic access to clinical data.   More recent literature has shown that clinical data 
and utilization history make the greatest contributions to predictive accuracy45,51 and improve 
model performance52.  
The majority of existing models tend to focus on risk of all-cause readmission for a pre-
selected cohort or for all patients hospitalized at the institution.  However, the discriminatory 
power of a predictive model can vary by more than 20% when the readmission diagnosis is 
changed51.  Models focusing on all-cause readmission are limited in their clinical utility to focus 
transition and post-discharge resources to patients who need them the most.  The ability to 
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predict the reason for readmission may guide more specific interventions by transition 
coordinators and population health managers.      
Despite the emergence of newer machine learning techniques, logistic regression remains 
the most common method for the development of readmission risk prediction models.  All 
models from the updated45 systematic review of hospital readmissions and all except one model49 
from the original systematic review44 continue to use logistic regression for model development.  
The most widely used models for readmission risk prediction in clinical practice are logistic 
regression models53, LACE54 and LACE+55.  LACE, developed in medical and surgical patients 
from 11 community hospitals in Ontario from 2004 to 2008, considers length of stay (L), acuity 
of the hospital admission (A), comorbidities (C) and emergency department visits in the previous 
6 months (E) to make a prediction.  During model evaluation, it demonstrated poor 
discrimination with a c-statistic of 0.684.  The acuity was determined by whether the admission 
was classified as emergent or elective.  Comorbidities were measured as the Charlson 
comorbidity index.  Charlson comorbidity index is a widely-used method for predicting mortality 
using weighted scoring of conditions56.  It includes weights for 17 conditions and has been 
validated across several clinical domains57–62.   It has also been adapted for use with ICD-9 
codes63.    The LACE+ model includes the predictors from the original LACE index and adds 
patient age and sex, teaching status of the discharge hospital, number of urgent admissions in 
previous year, number of elective admissions in previous year, case-mix group score and number 
of days on alternative level of care status.     
Newer machine learning algorithms have shown promise of improved performance 
compared with traditional logistic regression models, but have rarely been used in the evaluation 
of hospital readmissions.  Least absolute shrinkage and selection operator (LASSO), Random 
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Forest (RF) and Support Vector Machines (SVM) are novel machine learning techniques which 
are readily used in the biomedical literature across a wide array of clinical domains.  LASSO has 
been used to predict colon cancer diagnosis64, pancreatic cancer prognosis65, response to therapy 
in Schizophrenia patients66, mortality after violent crime67, hip fracture surgery68, sepsis69 cardiac 
procedures70, neurologic outcomes in pediatric intensive care unit patients71, pneumonia 
admissions in the general population72, infection after burn73 and hospital acquired pneumonia in 
stroke patient74 among others.  RF has seen application in non-small cell lung cancer response to 
chemotherapy75, infectious complications in combat casualties76, mortality in cholangitis77, 
sepsis78 and AMI79, Clostridium difficile recurrence80, severe Hand, Foot and Mouth disease81, 
cardiovascular event prediction82, extrauterine disease in patients with endometrial cancer 83 and 
relapse in childhood acute lymphoblastic leukemia (ALL)84.  Applications of SVM include 
prediction of post-operative sepsis and acute kidney injury (AKI)85, lung cancer86,  mortality 
after trauma87, sepsis88 and after cystectomy for bladder cancer89 and breast cancer survival90.     
Despite the promising results seen in other biomedical domains, there are few examples 
in the biomedical literature applying newer machine learning techniques to the prediction of 
unplanned hospital readmission.  Yu et al used an SVM framework to develop and evaluate 
institution-specific and diagnosis-specific readmission risk prediction models.  These were 
compared to a widely used logistic regression model, LACE91, and consistently demonstrated 
improved discrimination performance49.  Futoma et al directly compared the discrimination 
performance of logistic regression to several other commonly used statistical techniques 
including logistic regression with multi-step variable selection (LRVS), penalized logistic 
regression (PLR), RF and SVM.  The evaluation was performed across 280 cohorts as 
determined by the visit DRG and the same set of variable predictors was used in each.  RF and 
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PLR consistently outperformed all other techniques48.  Jamei et al analyzed several different 
methods including logistic regression, RF and artificial neural networks (ANN)92.  ANN 
demonstrated significantly greater performance than all other methods, including RF, the model 
with the second best performance.  Frizzell et al reported no difference in discrimination 
performance between naïve Bayesian network, RF, gradient-boosted logistic regression and 
LASSO models when applied to predict 30-day readmission in 56,477 Medicare patients with 
heart failure93.  In a study of short (30-day) and long-term (180-day) hospital readmission in 
patients with heart failure, Mortazavi et al demonstrated that RF and boosting improved 30-day 
all-cause and 30-day heart failure readmission, respectively, when compared to logistic 
regression94.   
 
Hospital Readmissions in Patients with Diabetes 
A review of existing literature reveals several studies describing independent risk factors 
for readmission in patients with diabetes.  Most of these studies use logistic regression to identify 
independent risk factors for readmission but do not assess the validity of the model or serve as a 
standalone tool.  Within a population of patients with diabetes, age95, race/ethnicity95–97, 
payer95,35, socioeconomic status95,97, source of admission98, comorbidities98–102, length of 
stay97,35, number of prescribers in previous year99, hospitalizations in the previous 6 months99, 
smoking status100, polypharmacy101, living in an urban setting103, presence of secondary 
hypoglycemia during admission104, and failure to record a diabetes diagnosis at discharge in 
patients with previous diabetes diagnosis105 are risk factors for 30-day hospital readmission.   
Three studies summarized in Table 2 present readmission risk prediction models developed in 
diabetes cohorts, evaluated in a separate validation sample and presented as standalone risk 
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prediction tools.  Their cohorts of study vary slightly but the features used to develop the 
algorithm are similar and they all evaluated the risk of all-cause readmission.  On internal 
validation, they each demonstrated acceptable or excellent discrimination but none of these used 
newer machine learning techniques which have shown promise to improve model performance in 
other readmission risk prediction models and other areas of study in biomedical literature.  
There are currently no published studies examining readmission risk in diabetes patients 
which use newer machine learning techniques or a diagnosis-specific readmission outcome 
to try to improve model performance and clinical utility. 
 
Table 2. Summary of Current, Internally Validated Readmission Risk Prediction Models in 
Patients with Diabetes 
 
Study Cohort Features Outcome Algorithm Internal  
Validation 
Rubin106 
2015 
 
DERRI 
Hospitalized 
patients with 
diabetes 
 
 Demographic 
 Laboratory 
 Medications 
 Microvascular 
complications 
 Utilization history 
30-day All-
Cause 
Logistic 
regression 
C-statistic 
0.69 
Rubin107 
2017 
 
DERRI-
CVD 
Patients 
with diabetes 
hospitalized for 
cardiovascular 
disease (CVD) 
 Comorbidities 
 Demographic 
 Laboratory 
 Medication 
 Microvascular 
complications 
 Visit utilization 
30-day All-
Cause 
Logistic 
regression 
C-statistic 
0.71 
 
 
Collins108 
2017 
Hospitalized 
Medicare 
patients with 
diabetes 
 Clinical 
conditions 
 Demographics 
 Utilization 
metrics 
*from claims data 
30-day All-
Cause 
Logistic 
regression 
C-statistic  
0.82 
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We hypothesize that a risk prediction model using novel machine learning techniques 
(LASSO, RF, SVM) to identify hospitalized patients with type 2 diabetes at highest risk of 
diagnosis-specific 30-day hospital readmission (DM and CHF) will outperform all-cause 
readmission, logistic regression-based prediction models.  First, we used LASSO, RF and SVM 
to develop and evaluate the validity of prediction models of hospitalized patients with type 2 
diabetes at risk for diagnosis-specific (DM, CHF, All-Cause) 30-day readmission.  Next, we 
compared these model performance metrics with the published and validated LACE all-cause 
readmission prediction tool.       
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CHAPTER 2 
 
METHODS 
 
Dataset 
We identified a retrospective cohort of inpatient admissions at Vanderbilt University 
Medical Center (VUMC) in Nashville, Tennessee, between October 1, 2010, and September 15, 
2015.  This time frame was selected to begin after the start of the initial HRRP benchmarking 
period to capture encounters over a relatively stable readmission reduction strategy.  The study 
population included adults aged 18 and older with type 2 diabetes (T2DM).  A diagnosis of 
T2DM was based on the presence of the PheWAS parent code 250.2 prior to the index 
encounter.  PheWAS is a research method which uses custom combinations of International 
Classification of Disease 9th edition (ICD-9) codes to describe phenotypes in electronic health 
record (EHR) data109,110.  Encounters for patients classified as “observation” status were 
excluded as only inpatient admissions are penalized under HRRP.         
Diagnosis Related Groups (DRG) and All Patient Refined Diagnosis Related Group 
(APR-DRG) were extracted for each inpatient encounter.  DRG is a framework for associating 
the types of conditions treated during a hospitalization with the costs associated with treating 
them.  APR-DRG is a proprietary classification scheme developed to enhance the traditional 
Diagnosis Related Group (DRG) classification of inpatient admissions by incorporating 
measures of severity of illness and risk of mortality111.  We used APR-DRG version 31112 to 
classify the reason for hospitalization and to define the diagnosis-specific 30-day readmission 
outcome.  All APR-DRGs except 693, chemotherapy, were included in the all-cause readmission 
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outcome.  Readmissions for chemotherapy were excluded from the outcome evaluation as these 
represent planned inpatient encounters which are not penalized under HRRP.   
While diabetes is a relatively less common reason for readmission among subjects in our 
cohort, it is a common chronic medical condition for which there are known strategies to reduce 
readmission.  Additionally, it is likely underrepresented as the primary reason for readmission 
due to its relatively lower service intensity weight.  Service intensity weight is a measure of cost 
or resources needed to treat an associated APR-DRG.  Given that the discriminatory power of a 
predictive model can vary significantly when the readmission diagnosis is changed51, we selected 
three readmission outcomes for which distinct models were developed.  In addition to predicting 
diabetes-specific readmissions, our original goal, we chose all-cause and heart failure APR-
DRGs as readmission outcomes of interest.  All-cause excluding chemotherapy was selected as 
this is the closest representation to the current HRRP implementation which penalizes all-cause 
unplanned readmissions for certain index admission diagnoses.  Heart failure is the most 
common reason for 30-day readmission in our population and is also one of the index 
hospitalizations penalized under HRRP. 
 Structured Query Language (SQL) was used to extract data from the 113, a database of 
clinical and related data derived from VUMC’s clinical systems and restructured for research.  
Data were preprocessed in Python114 before being imported into R115, an open-source software 
environment for statistical computing.  R was used for model development and internal 
validation.     
   
Feature Selection and Pre-Processing 
Features were selected based on domain expert opinion of those clinical variables 
relevant to the readmission risk of hospitalized patients with diabetes.  In order to support real-
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time application in a clinical setting, only those features that are available prior to discharge were 
included.  Features selected include demographic information, utilization history and laboratory 
results.  Table 3 describes features from each category used for training of all models. 
Demographic features include age, gender, race, insurance payer and area deprivation 
index.  Area of deprivation index is a geographically-based measure of socioeconomic 
deprivation associated with a 9-digit zip code116.  Because the full 9-digit zip code was not 
available for our cohort, we truncated area deprivation index 9-digit zip codes to include the first 
5 digits and assigned the median area deprivation index for each grouping.  Median, as opposed 
to mean, area deprivation index was chosen to reduce sensitivity to outliers.    
Utilization history included the length of stay (LOS) of the current admission, number of 
VUMC emergency department visits in the 6 months preceding admission, number of VUMC 
outpatient clinic visits in the 1 year preceding admission.  Six months was chosen as the 
lookback time for emergency department visits as this metric previously demonstrated validity in 
predicting hospital readmissions54.  In contrast, the cadence of many outpatient specialty 
appointments is less frequent so a longer lookback time of 1 year was used to capture outpatient 
utilization history. In addition, we chose to include active use of the locally-developed VUMC 
patient portal, My Health at Vanderbilt (MHAV), prior to the current admission as one of our 
utilization measures.  Patient portals are secure, internet-based platforms where patients may 
access their personal health information and communicate with health care providers.  Patient 
portal use has been associated with both no impact on117 and increased risk of118 30-day hospital 
readmission.   Utilization data for other hospitals were not available for inclusion.     
Laboratory tests included pre-admission and admission values.  Laboratory data ranges 
were reviewed and discarded where not physiologically possible.  We noted this systematic error 
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in point of care (POC) A1C values.  These likely represent transcription errors where laboratory 
equipment was not integrated with the EHR.  A1C values <2% and >25% were discarded as 
spurious, representing 0.03% of A1C readings.   
 
Table 3. Demographic, Utilization History, and Laboratory Results Used as Features in Model 
Training 
 
Feature 
Class 
Features 
Demographic o Age 
o Gender 
o Race 
o Insurance payer 
o Area deprivation index116 
Utilization 
History 
o Length of Stay 
o # VUMC emergency department visits in 6 months 
o # VUMC outpatient clinic visits in 1 year 
o Active use of VUMC patient portal  
Laboratory 
Results 
o Admission glucose 
o Admission bicarbonate 
o Maximum A1C in last 1 year 
o Boolean value representing if blood glucose checked on day of admission 
o Absolute value of difference between maximum and minimum creatinine 
during admission 
o Absolute value of difference between maximum and minimum sodium 
during admission 
o Absolute value of difference between maximum and minimum blood 
glucose during last 24 hours of the admission 
o Median number of blood glucose readings per day during the admission 
 
 
 
We evaluated candidate features for missingness.  For blood glucose, missing values may 
indicate patient or provider-specific characteristics related to the likelihood of hospital 
readmission.  For example, forgetting to check a blood glucose in a patient with diabetes could 
indicate substandard care delivery increasing the risk for readmission.  Alternatively, lack of 
blood glucose data on the day of admission may indicate that the patient has well-controlled 
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diabetes and admitted for routine hospital services with low risk of complication and 
readmission.  To address informative missingness, a Boolean variable was created to indicate 
whether or not blood glucose was measured on the day of admission.  All other missing data 
were assumed to be missing at random.   
Where data were missing at random, multiple imputation was used to replace missing 
values.  Multiple imputation uses bootstrapping, sampling with replacement from original non-
missing data, to replace missing values.  Then, using all cases from the imputed dataset, 
nonparametric regression is used to generate variable coefficients.  Using this model, predicted 
values are generated for all cases of the variable, missing and non-missing.  Last, predictive 
mean matching is used to fill in the original missing values.  With predictive mean matching, a 
missing value is filled from among the original non-missing values of that variable. Variables are 
randomly selected from cases where the regression-predicted values of the missing variables are 
closest to the regression-predicted value for the non-missing variables based on the simulated 
regression model.  We used the “Hmisc” package in R to generate 5 complete datasets119.  
 
Statistical Modeling  
A wide range of machine learning methods have been studied in the biomedical literature.  
Logistic regression remains a commonly used technique.  As a parametric method, it assumes the 
form of the unknown target function which offers both advantages and disadvantages.  Because 
the form and complexity of the target function are assumed, parametric methods require less 
computational time and less data to generate predictions.  However, they may suffer in accuracy 
if the assumptions do not match the underlying data.  Alternatively, nonparametric methods do 
not constrain the form of the target function.  As a result, the target function will change in shape 
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and complexity to best fit the underlying data.  This flexibility may offer improved accuracy 
compared to parametric methods but also increases the risk of overfitting.  Additionally, they 
may suffer from high computational time as they have more parameters to train.  We studied the 
behaviors of different machine learning techniques in current biomedical literature as discussed 
in Introduction.  Modern predictive studies should include both techniques in order to determine 
the optimal approach for the given problem.  In designing a data-driven model, it’s challenging 
to know which approach will best fit the problem a priori.  Based on methods used in prior 
readmission work, we selected one parametric and 2 nonparametric methods to study.    
LASSO is a form of penalized logistic regression where regularization parameters are 
used to reduce the magnitude of regression coefficients to avoid overfitting.  LASSO tends to 
select one predictor out of multiple correlated predictors and discards the others resulting in 
feature selection120.  An additional tuning parameter, λ, controls the overall strength of the 
penalty.  10-fold cross validation was used with each imputed dataset to select the shrinkage 
parameter λ.  LASSO was performed using the “glmnet” package in R.   
Unlike LASSO which assumes a constrained form of the mapping function, SVM with a 
radial kernel and RF are non-parametric methods.  RF uses bagging, selection of a random subset 
of observations and a random subset of features, to develop an ensemble of decision trees before 
polling the trees to create a ranking of classifiers121.  The use of bagging and random selection of 
features allow RF to overcome limitations such as sparse and missing data.  Our random forest 
models used 500 trees and were developed using the “ranger” package in R122.  We used 4 
variables available for splitting at each node, the default setting of the “ranger” package, 
determined as the rounded down square root of the number of predictor variables. 
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SVM attempts to find a hyperplane which separates observations of different classes123.  
Support vectors are the observations from each class closest to the hyperplane.  The best SVM 
model leaves the largest margin between support vectors of different classes and, thus, reduces 
overfitting.  Model margin of error and complexity are modified with two parameters, cost and γ.  
Lower cost values increase the margin to allow for incorrect classification.  The value of γ 
determines the complexity of the curve that best separates observations of different classes.  
When the value of γ is too large, overfitting will result.  For our model, we used γ = 1 and cost = 
1.25.  We used a radial kernel to develop a nonlinear classifier of the input data.  The “e1071” 
package in R was used to develop an SVM model for diabetes-specific readmission outcome124.   
For each of three readmission APR-DRGs, we developed prediction models using 
LASSO and RF.  SVM was also used for the development of a third model for diabetes-specific 
readmission (APR-DRG 420).  Due to high computational time and inferior performance as 
discussed in Results, we did not develop an SVM model for HF and all-cause readmission 
outcomes.   
In order to compare our models to the widely used LACE algorithm, we developed a 
univariate regression model with LACE score as the feature.  We evaluated the performance of 
this model across all three readmission outcomes studied. 
 
Internal Validation 
Internal validation involves using available data to estimate how well a given model will 
perform in a new dataset125.  Several strategies exist for performing internal validation.  In split-
sample validation, the observations are randomly divided into two sets, the training set and the 
testing set.  The training set is used to develop the model which is then evaluated in the testing 
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set.  While it benefits from computational simplicity, split-sample validation has several 
disadvantages.  First, the trained model may vary significantly depending on the split of the data, 
particularly if the predictors or outcome are skewed.  Similarly, because the evaluation is 
performed on a relatively small subset of the larger population, it may not provide a reliable 
estimate of how the model will perform in practice.    
Cross-validation is a variation on split-sample validation which can be used to yield a 
more consistent model.  To perform cross-validation, the data set is divided into some number of 
equally sized subsets.  One of the subsets is held out to serve as the test set while the remaining 
subsets serve as the training set for model development.  This approach of holding out one subset 
and training an all of the others is continued until each subset serves as the testing set one time.  
The average error across each of the testing sets is calculated.  This approach is less sensitive to 
variation based on the splitting of the data since all subsets serve as the test set once.  Because 
the final model has learned from all of the available data, the result demonstrates improved 
performance compared to split-sample validation.  However, it can be computationally intensive 
due to the need to repeatedly train the model125.       
Another approach is bootstrap validation126.  With this approach, the data are sampled 
with replacement to create subsets that are equal in size to the original data.  Prediction models 
are developed in each bootstrap subset and on the original data.  An evaluation of the difference 
in performance between them gives an estimate of accuracy.  Compared with split-sample and 
cross-validation, the estimate of model performance demonstrates less variability because the 
sizes of the subsets are equal to the size of the original.  Like cross-validation, it allows the 
model to train on all available data yielding a more accurate estimate.  Because of the need to 
repeatedly train models on bootstrapped subsets that are as large as the original data, it is more 
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computationally complex than split-sample and cross-validation.  Additionally, bootstrap 
validation has been demonstrated to work well in high-dimensional datasets where the number of 
predictors is much larger than the number of cases.  
For each model, we used Harrell’s algorithm127 for estimating optimism to calculate the 
optimism-adjusted performance of the model.  This method relies upon bootstrapping to quantify 
model optimism.   For each of 5 imputed complete datasets, models are developed and 
performance metrics calculated.  Each of the 5 datasets is then sampled with replacement 100 
times to create 100 new bootstrapped datasets for each.  Models developed and evaluated on 
bootstrapped samples are then evaluated on the imputed dataset from which they were derived.  
The difference in performance between the original dataset and bootstrapped datasets determines 
the degree of overfitting.  We followed Rubin’s rules for pooling results for combining results 
into an overall multiple imputation estimate128.  However, our results were not normally 
distributed based on an evaluation using the Kolmogorov-Smirnoy Goodness-of-fit test129  so we 
reported the median value of the performance metric.     
 
Model Performance Evaluation 
For each model, we report discrimination, calibration and a precision-recall curve.  
Discrimination, how well the model separates those with the outcome from those without, was 
assessed using the c-statistic.  For our binary outcome of hospital readmission within 30 days, 
this correlates to the area under the receiver operating characteristic (ROC) curve.  An ROC 
curve plots true positive rate (sensitivity) by false positive rate (1-specificity) over the range of 
possible cutoffs for classifying observations as positive or negative.  The c-statistic then 
represents the probability that a random observation with the outcome was given a higher score 
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than a random observation without the outcome.  C-statistic values may range from 0.5 to 1.0, 
where 0.5 implies that the model’s ability to accurately discriminate is equivalent to random 
chance and 1.0 implies perfect discrimination.  The “ROCR” package in R was used to generate 
ROC curves130.  Standard error was used to generate confidence intervals around the c-statistic 
for each test.   
For calibration, we report a calibration plot with its slope and intercept values.  The 
calibration plot is a graphical representation of predicted probability compared to observed 
probability.  For binary outcomes, where the observed probability is either 0 or 1, this plot was 
generated by binning observations into equal size groups based on an ordered list of predicted 
probabilities and plotting the proportion of outcomes per bin.  The “rms” package in R was used 
to create a calibration plot for one imputed dataset for each model126.  The calibration intercept 
measures the extent to which predictions are consistently too low or high using a comparison of 
the mean of all predicted risks to the mean observed risk46.  Calibration slope represents the 
degree of overfitting or underfitting by the regression coefficients where a slope less than 1 
suggests overfitting.131  A perfectly calibrated model is represented by a diagonal with slope = 1 
and an intercept = 0.  Calibration plots were made and slope and intercept values calculated 
using the val.prob function from the “rms” package in R126.                     
When evaluating a dataset with heavily imbalanced classes, additional measures are 
needed to present an accurate view of the model’s performance.  In this setting, ROC curves tend 
to present overly optimistic results132,133 as a high number of false positive have only a minimal 
effect on false positive rate.  Precision-recall curves can present a more accurate representation 
of model performance by accounting for the inappropriate labeling of false positive observations.  
This penalty for mislabeling negative outcomes is primarily accounted for in precision which 
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represents the fraction true positive cases out of all cases with a positive label (true positives plus 
false positives).  We used the “ROCR” package in R to create precision-recall curves for each of 
our models in order to present a more informative representation of our models’ performance in 
the setting of class imbalance.   
 
Feature Importance 
Feature selection is inherent to the LASSO algorithm but there may be inconsistency 
when evaluating models over several bootstraps.  We used the Bolasso algorithm to pool these 
results over 500 bootstraps (100 bootstraps for each of the 5 imputed datasets) 134.  Bolasso is a 
variable selection algorithm which finds the intersection of all features with non-zero weights in 
all bootstraps.  To calculate odds ratio and confidence intervals, we performed unregularized 
logistic regression using the Bolasso-selected features for each model and outcome.     
For each branch in a decision tree, RF uses Gini impurity to select the variable that 
provides the best split of the remaining observations122.  This method seeks the variable that 
accounts for the greatest variance in the data at each step.  For example, a feature which is 
present for 90% of the observations and not for 10%, has a higher Gini impurity than one present 
in 50% of observations.  We obtained the Gini impurity for all variables for each model and 
calculated the median Gini impurity across all imputed datasets to report these results.   
 
Clinical Application 
 
 In addition to considering performance evaluation metrics such as discrimination, 
calibration and precision, we want to know how best to apply the model in clinical practice.  We 
need to determine the optimal threshold for predicted probability.  Cases with a predicted 
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probability above that threshold are classified as having the outcome and cases with a predicted 
probability below that threshold are classified as not having the outcome.  We selected RF, the 
model with the best performance metrics, and created a confusion matrix at various outcome 
thresholds based on 30-day readmission for diabetes.  We randomly selected 112 encounters 
from our population.  None of those encounters were associated with a 30-day readmission for 
diabetes.  We also selected 3 observations with the outcome for a total of 115 patients.  This is 
equivalent to the average number of unique patients seen by the diabetes consult services in one 
week at VUMC.  Using this approach, the outcome prevalence for this subset of our population 
was 2% compared to the true outcome prevalence in our total population of 0.3%.  While we 
acknowledge this difference in outcome prevalence will impact our results, this exercise has 
utility in the demonstration of how to implement this model in clinical practice.  We also include 
a discussion of the limitations to this approach.            
We calculated the sensitivity, specificity and precision at various cutoffs.  Because 
hospital readmission for diabetes is a rare but serious event, we prioritized sensitivity over 
specificity and precision when selecting the ideal threshold.  Whereas sensitivity and specificity 
indicate a test’s ability to properly detect or reject cases, respectively, precision indicates the 
likelihood of the outcome given a positive test rest.  Unlike sensitivity and specificity, precision 
is affected by the prevalence of the outcome in the population.  With a lower outcome 
prevalence, we expect to see lower precision.  As such, we use this method to demonstrate how 
to apply this model in clinical practice but would need to evaluate prospectively to verify the 
validity. 
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CHAPTER 3 
 
RESULTS 
 
We identified 56,258 inpatient encounters for patients with type 2 diabetes admitted 
between October 1, 2010, and September 15, 2015.  The dataset included 29,013 unique patient 
identifiers of which 10,660 had more than one inpatient encounter during the study period.  
Table 4 presents the 10 most common 30-day readmission APR-DRGs in this cohort.  Although 
our population demonstrated a 17% rate of all-cause readmission within 30-days, our diagnosis-
specific readmissions had a low prevalence.  Heart failure was the single most common 
readmission diagnosis in our population and only accounted for 1% of the 30-day readmissions.  
While diabetes may have been a factor in many of the hospital readmissions, for reasons 
previously discussed, only 0.3% of the readmissions were coded with diabetes as the readmission 
diagnosis. 
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Table 4.  Summary of the 10 Most Common Readmission APR-DRGs for a Cohort of 56,258 
Inpatient Encounters of Adults with Type 2 Diabetes Over the Study Period Excluding APR-
DRG 693, Chemotherapy 
 
Readmission Reason 
(APR-DRG) 
Number of 30-day 
Readmissions 
(% of encounters) 
Number of unique patient 
identifiers 
All-Cause 9,762 
(17.4%) 
5,293 
Heart Failure 
(194) 
531 
(0.94%) 
394 
Septicemia and Disseminated 
Infections (720) 
440 
(0.78%) 
388 
Renal Failure 
(460) 
348 
(0.62%) 
311 
Post-operative, Post-traumatic or 
other device infections 
(721) 
344 
(0.61%) 
310 
Malfunction, Reaction & 
Complications of Genitourinary 
Device Or Procedure 
 (466) 
226 
(0.40%) 
182 
Diabetes 
(420) 
191 
(0.34%) 
133 
Cardiac Arrhythmia & 
Conduction Disorder 
(201) 
186 
(0.33%) 
162 
Other Pneumonia 
(139) 
171 
(0.30%) 
157 
Kidney & urinary tract infection 
(463) 
144 
(0.26%) 
131 
Percutaneous cardiovascular 
procedures without AMI 
(175) 
121 
(0.22%) 
116 
 
 
 The absence of a blood glucose check on day of admission may represent data which are 
missing not at random according to domain expert opinion.  To manage informative missingness, 
we added a Boolean variable to indicate whether or not the test was performed.  For all other 
features, we performed a missingness analysis with results as summarized in Table 5.     
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Table 5.  Summary of Missing Data 
Feature Number of missing values Proportion of encounters 
missing data 
Age 0 0 
Sex 0 0 
Race 0 0 
Payer 0 0 
ED visit count 0 0 
Outpatient Visit Count 0 0 
Glucose checked day of 
admission (yes/no) 
0 0 
MHAV Use (yes/no) 0 0 
LOS 5 0.001% 
Median BG readings per day 1839 3.3% 
Admission Glucose (1st day) 3464 6.2% 
Change in blood glucose last 24 
hours 
5917 10.5% 
Change in creatinine during 
admission 
6083 10.8% 
Change in sodium during 
admission 
6448 11.5% 
Area deprivation index 21511 38.2% 
A1C max (in last year) 21753 38.6% 
Admission bicarbonate 28217 50.2% 
Note. BG = blood glucose. ED = emergency department, MHAV = My Health at Vanderbilt 
patient portal, LOS = length of stay, A1C max = maximum A1C in the last year. 
 
 
 
 Predictive performance varied across readmission outcomes and statistical models.  
Optimism-adjusted discrimination results are presented in Table 6.  Across all readmission 
outcomes, RF demonstrated significantly better discriminatory performance than LASSO or 
SVM.  For diabetes-specific readmission, SVM had the lowest discriminatory performance and 
highest computational time and, therefore, was not used to develop models for heart failure and 
all-cause readmission.  LASSO performed significantly better for both diagnosis-specific 
readmission outcomes than for all-cause readmission.  While there was less variation in the 
discriminatory performance of RF across readmission outcomes, RF did demonstrate a 
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statistically significant improvement in performance for diabetes-specific readmission when 
compared to all-cause or heart failure readmissions.    
LACE demonstrated inferior discriminatory performance in predicting all-cause 
readmission in our population than it did at model development54.  While developed to predict 
all-cause readmission, LACE demonstrated its best discriminatory performance when predicting 
heart failure readmission in our external validation.  It was no better than chance at predicting 
readmission for diabetes.  Across all readmission outcomes, LACE demonstrated inferior 
discriminatory performance in this external validation when compared to our models. 
 
Table 6. Discriminatory Performance of Each Statistical Model Across all Readmission 
Outcomes 
 
Statistical Model 
Readmission Outcome 
ROC (95% CI) 
Diabetes Heart Failure All-Cause 
LASSO 0.85 
(0.849-0.850) 
0.71 
(0.709-0.710) 
0.64 
(0.648- 0.648) 
RF 0.95 
(0.949-0.951) 
0.93 
(0.929-0.931) 
0.94 
(0.939-0.940) 
SVM 0.84 
(0.838-0.842) 
--- --- 
LACE  0.477 0.670 0.594 
 
 
 
   To assess calibration, we measured calibration slope and intercept and examined a 
calibration plot for each model.   Optimism-adjusted calibration performance metrics for slope 
and intercept are summarized in Table 7.  LASSO demonstrated the most consistent and well-
calibrated models with slope near 1 and intercept near 0 for all models.  SVM demonstrated poor 
calibration with a slope indicating the model underfit the data and an intercept indicating 
predictions are systematically too high.  RF tended to underfit data, more for all-cause 
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readmission than for diagnosis-specific readmission.  RF also demonstrated a slight tendency for 
high predictions, particularly in heart failure and all-cause readmission outcomes, when 
compared with LASSO.       
 
Table 7. Calibration Performance of Each Statistical Model Across all Readmission Outcomes 
Statistical 
Model 
Readmission Outcome 
Diabetes Heart Failure All-Cause 
Slope Intercept Slope Intercept Slope Intercept 
LASSO 0.9924598 -0.0423310 0.97364 -0.1168155 1.000334 -0.0015909 
RF 3.273016 0.5016695 2.679752 2.71451577 7.267741 2.2598 
SVM 14.5954 70.4701 --- --- --- --- 
 
 
  
Whereas slope and intercept rely on a single value to describe model fit and systemic 
tendency for high or low predictions, calibration plots show cases where the model calibration 
may vary across the distribution of observations.  A single, representative calibration plot for 
each model is shown below in Figure 1.  For each plot, a gray, shaded line along the diagonal 
represents ideal calibration.  A darker, solid, gray line plots the logistic calibration curve.  The 
logistic calibration curve represents the proportion of outcomes per bin when observations are 
grouped into equal size bins based on an ordered listed of predicted probabilities.  This is useful 
when plotting calibration for a binary outcome.  LASSO demonstrates good calibration across all 
readmission outcomes.  Compared to LASSO, RF demonstrated inferior calibration across all 
models, particularly for all-cause readmission.  However, the calibration plots show that the RF 
models for diabetes and heart failure readmission outcomes demonstrated reasonable calibration 
at low outcome probabilities.  SVM demonstrated poor calibration at all outcome probabilities 
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when evaluated for diabetes readmission.  Given these results and SVM’s inferior discriminatory 
performance, we did not use SVM to develop CHF or all-cause readmission models.    
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Figure 1. LASSO, RF and SVM Calibration Plots for Diabetes, Heart Failure and All-Cause 
Readmission Outcomes 
 
A.  Diabetes—LASSO         B.  Diabetes—RF  
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Note. 1A, 1B and 1C demonstrate a representative calibration curve from a single bootstrap for 
LASSO, RF and SVM, respectively, when evaluated for diabetes-specific readmission.  1D and 
1E show representative plots for LASSO and RF, respectively, for heart failure readmission.  1F 
and 1G display a representative calibration plot for LASSO and RF when evaluated for all-cause 
readmission.  For each plot, the light gray, shaded line along the diagonal represents ideal 
calibration.  The darker, solid gray line plots the logistic calibration curve in which we are most 
interested.  
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 To evaluate the calibration of LACE, we used the univariate logistic regression model 
with LACE score as the variable to plot the mean predicted probability at each LACE score 
against the outcome proportion at each LACE score.  These plots are shown in Figure 2 below.  
The maximum outcome proportion for diagnosis-specific readmission outcomes is much lower 
than for all-cause readmission as reflected by variation in the y-axis scale on these figures.  This 
reflects the overall low prevalence of diabetes and heart failure-specific readmission outcomes in 
our population.  For all-cause readmission, this model demonstrated good calibration, 
particularly at lower LACE scores where there were more observations.  For the diagnosis-
specific readmission outcomes, the calibration is not as good but is difficult to evaluate given the 
low prevalence of the outcome at some LACE scores.   
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Figure 2. Calibration Plots for LACE Score Univariate Regression Model for Each Readmission 
Outcome 
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 In a skewed dataset where the number of outcomes is rare, precision can give a more 
accurate representation of model performance by accounting for the number of false positives.  
With a rare outcome, a model may demonstrate excellent discrimination simply with a base-rate 
classifier which has a high true positive rate but also a high number of false positive results.  
Figure 3 illustrates precision-recall curves for each readmission outcome.  LASSO demonstrates 
poor precision across all models, particularly for diagnosis-specific readmission outcomes.  
Despite demonstrating poor discrimination and calibration, compared with LASSO, SVM more 
accurately labeled negative outcomes resulting in better precision.  RF demonstrated excellent 
precision and recall for all models.   
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Figure 3. Precision-Recall Curves for LASSO, RF and SVM Models for Each Readmission 
Outcome 
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Because the precision of RF appears to be spuriously high, we examined it more closely 
at low thresholds near the outcome prevalence for diabetes.  These results can be seen in Figure 
4.  At low thresholds, the precision for RF is very low but it rises quickly with increasing 
threshold.  Choosing the threshold based on outcome prevalence alone will result in a model with 
low precision due to a high number of false positives.  This could lead to misallocation of 
resources to patients who have low risk of readmission.  As a result, we will want to select the 
predicted risk threshold at which we would implement the model in clinical practice based on 
optimizing sensitivity, specificity and precision.     
 
 
 
 
 
--- LASSO 
--- RF 
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Figure 4.  Plots of Precision Versus Threshold for RF Model on DM Outcome 
 
Note. Precision is poor at low thresholds, including the outcome prevalence of 0.3%, but rises 
quickly with increasing threshold. 
 
 
 
The features selected by the Bolasso algorithm for each readmission outcome are shown 
in table 8 below.  All selected features were statistically significant with p-value <0.001 except 
race in the heart failure readmission model.  Of the 17 features included in model development, 
12 were selected after Bolasso evaluation for at least one readmission outcome.  Payer, length of 
stay, area deprivation index, change in creatinine during admission and use of the patient portal 
did not appear in any model.  Only two features (age and number of emergency department visits 
in previous 6 months) were selected by the Bolasso for all 3 readmission outcomes.     
In all 3 models, more emergency department visits were associated with an increased risk 
of readmission.  Compared with the heart failure readmission model where higher age increased 
the risk of readmission, increasing age was associated with a slightly reduced risk for 
readmission in diabetes-specific and all-cause readmission models.  While this counterintuitive 
to clinical intuition, the odds ratio in both of these models was very close to 1.  One other 
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consideration to explain this result is death as a competing risk with increasing age.  While we 
considered the impact of death on readmission risk, it was not directly modeled.     
 For diabetes-specific readmission, 2 other features were associated with a reduced risk of 
readmission.  These included blood glucose being checked on day of admission and increasing 
admission bicarbonate.  Both are clinically plausible.  Monitoring blood glucose upon admission 
indicates and awareness of and attention to diabetes management by the clinician.  Low 
bicarbonate values indicate acidosis, a serious condition associated with some diabetes-related 
conditions.  Elevated A1C indicates poorly controlled diabetes which increases risk of 
cardiovascular disease and stroke as well as numerous other diabetes-related conditions135 so it is 
not unexpected to see that as one of the strongest predictors of hospital readmission in patients 
with diabetes.     
 Some of the same features present in the diabetes-specific model were also present in the 
heart failure model, but a few new features also emerged.  A larger change in sodium during the 
hospital admission was associated risk of readmission.  Sodium alterations can exist in a number 
of complex medical conditions including diabetes, renal failure, liver failure, nutritional 
deficiency and heart failure among others.  Heart failure is the only Bolasso model selecting race 
as a feature.  While none reach statistical significance in the unregularized regression model, 
black, other, and unknown race were associated with higher risk of readmission compared to 
white race.  The effect of race on heart failure prognosis is mixed in reported literature136–139.   
 The Bolasso all-cause model is the only one to select sex as a feature with male sex 
indicating an 11% increased risk of readmission compared to female.  Two measures of 
utilization history, emergency department visits in 6 months and outpatient visits in 1 year, 
appear in the all-cause readmission model.  Several of the laboratory values present in either the 
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diabetes or heart failure models appear in the all-cause model including change in blood glucose 
in last 24 hours of admission, change in sodium during admission and admission glucose.  All 
are likely markers of disease severity and complexity.     
 
Table 8. Features Selected from LASSO Models Using Bolasso Algorithm With OR and P-value   
Features 
Readmission Diagnosis 
DM HF All-Cause 
A1c max (in last 
year) 
1.2752145* 1.096570*  
Age 0.9729791* 1.039310* 0.9924642* 
Median BG readings 
per day 
1.1663328*   
Admission 
bicarbonate 
0.8061060*   
Change in BG (in last 
24 hours) 
1.0041854*  1.0008262* 
Change in sodium 
during admission 
 1.054966* 1.0390031* 
ED visit count (in 6 
months) 
1.1070867* 1.132465* 1.1618994* 
Admission Glucose 
(1st day) 
  0.9991449* 
Glucose checked day 
of admission (yes/no) 
0.1758684*  1.4191464* 
Outpatient Visit 
Count (in last year) 
 1.015681* 1.0143048* 
Race  Black 3.508632  
(p= 0.0789) 
Other 3.610592 
(p=0.1626) 
Unknown 3.828665  
(p=0.3380) 
White 2.165657 
(p=0.2772) 
 
Sex   Male 1.1130738* 
Note. All features selected demonstrate statistical significance except race in the LASSO heart 
failure model. *p-value <0.001. BG = blood glucose, ED = emergency department, A1C max = 
maximum A1C in the last year. 
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 Random forest evaluates the amount of variance explained by a variable with each split 
of the decision tree.  This is reported as importance.  Table 9 summarizes the feature importance 
results from all three random forest models.  It is notable that age is reported as the most 
important feature in all 3 RF models and admission glucose is the 2nd.  Age was one of only two 
features selected in all 3 Bolasso evaluations.   
Whereas no markers of socioeconomic status appeared in any of the final Bolasso 
models, area deprivation index appeared in the top 5 importance for all 3 RF models.  This 
supports prior work140,141 which found that low socioeconomic status was associated with an 
increased risk for readmission likely due related to low self-efficacy, low health literacy and 
limited access to healthcare resources142.     
Laboratory values including admission glucose, change in creatinine during admission, 
change in blood glucose in last 24 hours of admission and max A1C in last year make up the 
remainder of the top 5 across all RF models.  Variation in blood glucose and creatinine during 
the admission reflect the severity and lability of the underlying disease.  Alterations in kidney 
function, as reflected by changes in serum creatinine, directly impact glycemic control due to the 
role kidneys play in the metabolism of insulin.  Labile renal function can cause a broad range of 
glycemic excursions which may include hypoglycemia with impaired renal function due to 
reduced insulin degredation or hyperglycemia if renal function improves and insulin metabolism 
is increased.  Additionally, if glycemic control is highly labile in the hospital where dietary 
choices and physical activity are often more consistent than what patients experience when not 
hospitalized, it is clinically plausible that diabetes will also be difficult to control after discharge, 
placing the patient at increased risk for readmission.  Admission glucose and maximum A1C in 
the last year are more likely to reflect a patient’s capacity for self-care.  The goal of many care 
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transition programs is to increase the patient’s capacity for self-care, however, these are time and 
resource-intensive efforts which are often difficult to sustain.  
The 5 least important variables were the same across all 3 RF models.  These are payer, 
race, use of the patient portal MHAV and whether or not blood glucose was checked on 
admission.  With the exception of race, which did appear in the Bolasso model for heart failure 
readmission but did not reach statistical significance on unregularized regression, these are the 
same features that did not appear in the final Bolasso model for any outcome.   The inclusion and 
exclusion of many of the same features between LASSO and RF supports the validity of their 
findings. 
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Table 9.  Random Forest Feature Importance for Diabetes, Heart failure, and All-Cause 
Readmission Models 
 
Importance Diabetes Heart Failure All-Cause 
1 Age Age Age 
2 Admission Glucose Admission Glucose Admission Glucose 
3 A1C Max Change in Blood 
Glucose 
Area deprivation 
index 
4 Change in Blood 
Glucose 
Change in creatinine A1C Max 
5 Area deprivation 
index 
Area deprivation 
index 
Change in creatinine 
6 Change in creatinine A1C Max Outpatient visit count 
7 Median BG readings 
per day 
Outpatient visit count Change in Blood 
Glucose 
8 Outpatient visit count LOS LOS 
9 Admission 
bicarbonate 
Admission 
bicarbonate 
Admission 
bicarbonate 
10 ED visit count Change in sodium Change in sodium 
11 Change in sodium ED visit count ED visit count 
12 LOS Median BG readings 
per day 
Median BG readings 
per day 
13 Payer Payer Payer 
14 Race Race Race 
15 MHAV Use Sex Sex 
16 Sex MHAV Use MHAV Use 
17 Glucose checked day 
of admission 
Glucose checked day 
of admission 
Glucose checked day 
of admission 
Note. Features with higher importance measures explain greater variance in the data.  BG = 
blood glucose.    
 
 
 
Clinical Application 
In order to simulate a population of patients seen by the Endocrinology consultation 
service at VUMC in 1 week, we identified a subset of our population containing 115 
observations.  Of those, 112 were randomly chosen and included no cases.  Three cases were 
randomly selected for inclusion in order to enable us to perform the evaluation.  This outcome 
prevalence of 2% is much greater than 0.3%, the true outcome prevalence in our population.   
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While this difference will impact our results, we will discuss these limitations and recognize the 
value of this exercise in demonstrating how we could implement our model in clinical practice.   
We evaluated sensitivity, specificity and precision of the classification at various 
predicted probability thresholds.  Results of the evaluation are summarized in table 10.  This 
model suffers from poor precision at our true outcome threshold of 0.3% but improves with 
increasing cutoffs for the threshold.  For this rare but serious outcome, we prioritize sensitivity to 
ensure all at risk patients receive the intervention.  Based on these results, we can achieve ideal 
sensitivity, specificity and precision at a threshold of 0.075 (or 7.5% risk of readmission) 
allowing us to match our resources with the highest-risk patients.  Using this example, we would 
recommend the intervention for a patient with a predicted probability of readmission 7.5% or 
greater.   
Given that the outcome prevalence of 2% in our example is much greater than that of the 
underlying population, this evaluation likely overestimates the true precision and needs 
prospective, external validation.  As demonstrated in Figure 4 above, precision across the entire 
population from a 5 year period is poor at low threshold values, including the outcome 
prevalence of 0.3%, but becomes 1 at a threshold of 35% where sensitivity and specificity are 
also calculated to be 1.     
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Table 10.  Sensitivity, Specificity, and Precision Evaluation of 115 Observations, Including 3 
Cases of Diabetes-Specific Readmission 
        
Threshold FN FP TN TP 
Precision 
(PPV) 
Sensitivity 
(Recall) Specificity 
0.002 0 16 96 3 0.16 1.00 0.86 
0.003 0 9 103 3 0.25 1.00 0.92 
0.005 0 6 106 3 0.33 1.00 0.95 
0.007 0 4 108 3 0.43 1.00 0.96 
0.008 0 4 108 3 0.43 1.00 0.96 
0.009 0 4 108 3 0.43 1.00 0.96 
0.01 0 4 108 3 0.43 1.00 0.96 
0.015 0 4 108 3 0.43 1.00 0.96 
0.02 0 3 109 3 0.50 1.00 0.97 
0.03 0 3 109 3 0.50 1.00 0.97 
0.05 0 1 111 3 0.75 1.00 0.99 
0.075 0 0 112 3 1.00 1.00 1.00 
0.1 0 0 112 3 1.00 1.00 1.00 
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CHAPTER 4 
 
CONCLUSIONS 
 
 This study presents the performance of three machine learning methods to predict three 
different 30-day readmission outcomes.  We used LASSO, RF and SVM to predict unplanned 
30-day readmission for diabetes.  Due to the inferior performance and high computational time 
associated with SVM, we used only LASSO and RF to predict unplanned readmission for heart 
failure and all-cause readmission.   
RF offered the best discriminatory performance among all models across all three 
readmission outcomes.  While it was not as well-calibrated as LASSO, next steps would include 
the implementation of techniques such as binning, Platt scaling or isotonic regression to improve  
calibration143.  Additionally, many of our performance metrics for RF seem high.  While there is 
literature supporting similar behavior of these methods in other settings, given our great class 
imbalance, we are concerned that our results may represent overfitting.  Future work should also 
include other methods such as oversampling and undersampling in attempt to avoid overfitting in 
a highly imbalanced dataset.   
While LASSO’s discriminatory performance was not as high as RF, it demonstrated 
excellent discrimination for diabetes-specific readmission and acceptable discrimination for heart 
failure-specific readmission.  Its discriminatory performance is also superior to the readmission 
prediction models most commonly used in clinical practice91.  LASSO benefits from low 
computational time.   Additionally, LASSO is well-calibrated for all outcomes so it would not 
require recalibration methods which may impact discriminatory performance.  Lastly, the 
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features selection aspect of LASSO improves the interpretability of the results.  These 
advantages of LASSO make it an important model to consider, possibly in combination with 
other methods, for future application.                  
The informatics contribution of this work is the application of newer machine learning 
techniques to a novel population and evaluating the performance while varying the outcome of 
interest.  It also demonstrated the value of using domain knowledge in the development pipeline 
and not solely relying upon available structured data.  This builds on the large body of 
readmission prediction model literature which consists mostly of logistic regression models with 
an overemphasis on administrative billing data to predict all-cause readmission.  
  Clinically, there has been little work predicting readmission in patients with diabetes.  Of 
the three published studies, none use novel machine learning approaches and none are 
considering outcomes other than all-cause readmission which limits their utility and impacts their 
model performance.  We expand that body of knowledge by adding new methods to the approach 
of hospital readmission risk prediction for patients with diabetes.  Additionally, by predicting 
diagnosis-specific readmission, our results are directly actionable by a diabetes, or other disease-
specific, service line.       
 There are several strengths to our approach.  One is the use of both parametric and 
nonparametric methods applied to our population of interest.  It’s difficult to know a priori which 
method will best suit the problem and this approach enables comparison across methods while 
maintaining consistency of the underlying data.  Another is the use of domain expertise to select 
and transform data for inclusion as features in our study.  This, in combination with presentation 
of selected features and feature importance from LASSO and RF, respectively, leads to models 
which are clinically meaningful and more likely to be accepted by end users.  It may also explain 
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why our models performed so well with relatively few features.  Because we are predicting the 
specific reason that the patient is returning to the hospital, a disease-specific service line can 
target disease-specific interventions to highest-risk patients in attempt to prevent the 
readmission.  Unlike some all-cause readmission prediction models, the output is focused and 
actionable related to a specific condition.     
 One of the limitations of our study is an academic medical center as the single source of 
data which may impact the generalizability of the results.  Additionally, we did not have data 
regarding utilization history and readmissions to other facilities which could skew our results and 
underestimate the outcome prevalence.  Another important limitation to our study is the use of 
APR-DRG to define readmission diagnosis, particularly for the diabetes outcome.  In the current 
reimbursement structure, APR-DRG is used to determine payment for a hospitalization based on 
service intensity weight.  Medical coders will look for criteria to assign the APR-DRG with the 
highest possible service intensity weight to the admission in order to maximize reimbursement.  
Because the service intensity weight for diabetes is low, medical coders will look for almost any 
other APR-DRG to define the hospitalization even if diabetes is or is not directly related to the 
true reason for admission.  Lastly, while we consider it a strength to use domain expertise in the 
pre-selection of model features, one could consider an argument for allowing the models to use 
as much available clinical data as possible.                  
 Future work must include a prospective evaluation of performance validity in order to 
address the above limitations and understand the degree of overfitting of the results.  Future 
research should also include enhancement of the methods used to assign readmission for 
diabetes.  This could include natural language processing to evaluate documentation during the 
admission as well as other tools to develop a phenotype based on any available EHR data.      
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